Publications
At Phathom, we encourage the publication of scientific information in peer-reviewed publications and at scientific meetings. Key publications of interest are included below.
Some of the publications include data for investigational uses of vonoprazan. Phathom makes no representation as to the safety or efficacy of vonoprazan for investigational uses.
Treatment of Heartburn in Non-Erosive Reflux Disease
Clinical Gastroenterology and Hepatology– 2024
Vonoprazan is Efficacious for Treatment of Heartburn in Non-Erosive Reflux Disease: A Randomized Trial
Laine L et al.
Healing and Maintenance of Healing of Erosive Esophagitis
Gastroenterology – 2022
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Laine L et al.
Eradication of H. pylori infection
Gastroenterology – 2022
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
Chey W et al.
Treatment of Heartburn Associated with Non-Erosive GERD
Alimentary Pharmacology & Therapeutics – 2023
Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease
Fass R et al.
Alimentary Pharmacology & Therapeutics – 2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection
Scarpignato C et al.
Clinical Pharmacology in Drug Development – 2021
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
Darcy M et al.
Scientific Congresses
Real-World Demographic and Clinical Characteristics of Vonoprazan-Treated U.S. GERD Patients
DDW – 2025
Real-World Demographic and Clinical Characteristics of Vonoprazan-Treated Patients in the United States Diagnosed With GERD: A Descriptive Analysis of Non-Erosive vs. Erosive GERD
Shah E, et al.
Real-World Treatment Patterns of Prior Lines of PPI Therapy in Vonoprazan-Treated U.S. GERD Patients
DDW – 2025
Real-World Treatment Patterns of Prior Lines of PPI Therapy in Vonoprazan-Treated Patients in the United States Diagnosed with Non-Erosive or Erosive GERD
Shah E, et al.
Evaluating On-Demand Vonoprazan Treatment for Non-Erosive GERD
ACG – 2024
Heartburn Frequency and Symptom Improvement Rates of Treated Episodes When Switching from Daily to On-Demand Vonoprazan Treatment for Non-Erosive Reflux Disease
Fass R, et al.
Nocturnal GERD Symptoms in Non-Erosive GERD
ACG – 2024
Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease
Antunes C, et al.
Treatment of Heartburn in Non-Erosive Reflux Disease
DDW – 2024
Vonoprazan for the Treatment of Heartburn in Non-Erosive Reflux Disease: A Randomized Trial
Laine L, et al.
Health Care Resource Utilization with Erosive Esophagitis
DDW – 2024
Erosive Esophagitis is Associated with High Health Care Resource Utilization and Frequent Changes in Medication
Shaheen N, et al.
Newly Diagnosed Erosive Esophagitis Patient Real-World Treatment Patterns
DDW – 2024
Real-World Treatment Patterns among Newly Diagnosed Patients with Erosive Esophagitis in the U.S.
Patel D, et al.
Local Investigator-Reported vs Centrally Adjudicated Los Angeles Grades of Erosive Esophagitis
DDW – 2024
Comparison of Local Investigator-Reported vs Centrally Adjudicated Los Angeles Grades of Erosive Esophagitis in Patients Screened for Participation in a Randomized Trial
Spechler S, et al.
Analyzing the Relationship Between pH Control and Erosive Esophagitis Healing Rates
DDW – 2023
A Model-Based Meta-Analysis of the Relationship Between pH Control and Erosive Esophagitis Healing Rates
Howden C, et al.
H. Pylori Eradication Rates with Vonoprazan
DDW – 2023
Helicobacter pylori Eradication Rates with Vonoprazan: Subgroup Analysis from the Phase 3 pHalcon-HP Trial
Chey W, et al.
Evaluating Vonoprazan vs. Placebo in the Treatment of Heartburn in NERD
ACG – 2022
Efficacy and Safety of On-Demand Vonoprazan versus Placebo in the Treatment of Heartburn in Symptomatic Nonerosive Reflux Disease (NERD) Patients: A Phase 2 Randomized Controlled Trial
Fass R, et al.
Pharmacodynamics and Pharmacokinetics of Vonoprazan
ACG – 2022
Development and Utilization of a Pharmacokinetic/Pharmacodynamic Model for Vonoprazan to Assess the Relationship Between Dose, Exposure, and pH Holding-Time Ratio
Scarpignato C, et al.
Healthcare Cost Savings Following Successful H. Pylori Eradication
AMCP Nexus – 2022
Healthcare Cost Savings in the Year Following Successful Eradication of Helicobacter pylori With Current US Guideline-Recommended Treatment
Shah S, et al.
Pharmacodynamics and Pharmacokinetics of Vonoprazan
DDW – 2022
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in U.S. Subjects
Laine L, et al.
Impact of Moderate and Strong CYP3A Inducers on Vonoprazan Exposure
DDW – 2022
Novel Approach to Evaluate the Impact of Moderate and Strong CYP3A Inducers on Vonoprazan Exposure
Ramsden D, et al.
Global Trends in Efficacy of Clarithromycin-Containing Regimens in H. pylori Eradication
DDW – 2022
Global Temporal Trends in the Efficacy of Clarithromycin-Containing Regimens in Helicobacter Pylori Eradication
Moss F S, et al.
Diagnosis and Treatment Patterns Among U.S. H. pylori Patients
DDW – 2022
Diagnosis and Treatment Patterns Among Patients with Helicobacter pylori Infection in the United States: A Linked EMR-Claims Database Analysis
Shah S, et al.
Comparative Efficacy of H. pylori Eradication Therapies
DDW – 2022
Comparative Efficacy of Helicobacter Pylori Eradication Therapies: A Network Meta-Analysis
Malfertheiner P, et al.
Comparative Efficacy of Acid Suppression Backbones for H. pylori Eradication
DDW – 2022
Comparative Efficacy of Acid Suppression Backbones for Helicobacter Pylori Eradication: Results of a Network Meta-Analysis
Malfertheiner P, et al.
Effect of Vonoprazan on the Pharmacokinetics of Midazolam
DDW – 2022
A Clinical Drug Interaction Study to Assess the Effect of Vonoprazan on the Pharmacokinetics of Midazolam
Mulford D J, et al.
*The publications contained in this section are provided for informational purposes only. The information contained in each publication is accurate only as of the date it was originally issued and is not controlled by Phathom. Phathom assumes no responsibility for the information or statements in such publications and disavows any obligation to update the information contained in such publications after the date of their issuance.